Prevention of mother-to-child transmission of HIV

Handbook of Pediatric HIV Care, Second Edition

Volumn , Issue , 2006, Pages 107-133

  Read, Jennifer S ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67650800609     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511544781.006     Document Type: Chapter

References (102)

1. UNAIDS. AIDS Epidemic Update: December 2003 (Available at www. unaidṣorg).
2. Kourtis, A. P., Bulterys, M., Nesheim, S. R., Lee, F. K. Understanding the timing of HIV transmission from mother to infant. J. Am. Med. Assoc. 2001; 285: 709-712.
3. Working Group on Mother-to-Child Transmission of HIV. Rates of mother-to-child transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1995; 8: 506-510.
4. Fowler, M. G., Simonds, R. J., Roongpisuthipong, A. Update on perinatal HIV transmission. Pediatr. Clin. North Am. 2000; 47: 21-38.
5. Contopoulos-Ioannidis, D. G., Ioannidis, J. P. A. Maternal cell-free viremia in the natural history of perinatal HIV-1 transmission. J. Acquir. Immune Defic. Syndr. 1998; 18: 126-135.
6. Mofenson, L. M., Lambert, J. S., Stiehm, E. R. et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N. Engl. J. Med. 1999; 341: 385-393.
7. Cooper, E. R., Charurat, M., Mofenson, L. et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J. Acquir. Immune Defic. Syndr. 2002; 29: 484-494.
8. Shapiro, D., Tuomala, R., Pollack, H. et al. Mother-to-childHIVtransmission risk according to antiretroviral therapy, modeof delivery, andviral load in 2895 U. S. women(PACTG 367). EleventhConferenceonRetrovirusesandOpportunistic Infections(February2004; San Francisco, CA.), Program and Abstracts. (Abstract S-80).
9. Connor, E. M., Sperling, R. S., Gelber, R. et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N. Engl. J. Med. 1994; 331: 1173-1180.
10. Shaffer, N., Chuachoowong, R., Mock, P. A. et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999; 353: 773-780.
11. Wiktor, S. Z., Ekpini, E., Karon, J. M. et al. Short-course zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999; 353: 781-785.
12. Dabis, F., Msellati, P., Meda, N. et al. 6-month efficacy, tolerance and acceptability of a short regimenof oral zidovudine to reduce vertical transmission ofHIVin breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 1999; 353: 786-792.
13. Leroy, V., Karon, J. M., Alioum, A. et al. Twenty-four month efficacy of a maternal shortcourse zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. AIDS 2002; 16: 631-641.
14. Lallemant, M., Jourdain, G., Le Coeur, S., et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N. Engl. J. Med. 2000; 353: 982-991.
15. Jackson, J. B., Musoke, P., Fleming, T. et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362: 859-863.
16. ThePetra study team. Efficacy of three short-course regimensof zidovudineandlamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomized, double-blind, placebocontrolled trial. Lancet 2002; 359: 1178-1186.
17. Moodley, D., Moodley, J., Coovadia, H. et al., for the South African IntrapartumNevirapine Trial (SAINT) Investigators. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J. Infect. Dis. 2003; 187; 725-735.
18. Dorenbaum, A., Cunningham, C. K., Gelber, R. D. et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. J. Am. Med. Assoc. 2002; 288: 189-198.
19. Lallemant, M., Jourdain, G., Le Coeur, S., et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N. Engl. J. Med. 2004; 351: 217-228.
20. Sperling, R. S., Shapiro, D. E., Coombs, R. W. et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N. Engl. J. Med. 1996; 335: 1621-1629.
21. Ioannidis, J. P. A., Abrams, E. J., Ammann, A. et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J. Infect. Dis. 2001; 183: 539-545.
22. Wade, N. A., Birkhead, G. S., Warren, B. L. et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N. Engl. J. Med. 1998; 339: 1409-1414.
23. Wade, N. A., Birkhead, G. S., French, P. T. Short courses of zidovudine and perinatal transmission of HIV [letter] N. Engl. J. Med. 1999; 340: 1042-1043.
24. Chuachoowong, R., Shaffer, N., Siriwasin, W. et al. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. J. Infect. Dis. 2000; 181: 99-106.
25. John, G. C., Nduati, R. W., Mbori-Ngacha, D. A. et al. Correlates of mother-to-child humanimmunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J. Infect. Dis. 2001; 182; 206-212.
26. Mandelbrot, L., Msellati, P., Meda, N. et al. 15 month follow up of African children following vaginal cleansing with benzalkonium chloride of their HIV infected mothers during late pregnancy and delivery. Sex. Transm. Infect. 2002; 78: 267-270.
27. Biggar, R. J., Miotti, P. G., Taha, T. E. et al. Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet 1996; 347: 1647-1650.
28. Gaillard, P., Mwanyumba, F., Verhofstede, C. et al. Vaginal lavage with chlorhexidine during labor to reduce mother to child HIV transmission: clinical trial in Mombasa, Kenya. AIDS 2001; 15: 389-396.
29. Wilson, C., Gray, G., Read, J. S. et al. Tolerance and safety of different concentrations of chlorhexidine for peripartum vaginal and infant washes: HIVNET 025. J. Acquir. Immune Defic. Syndr 2004; 35: 138-143.
30. Semba, R. D., Kumwenda, N., Hoover, D. R. et al. Humanimmunodeficiencyvirus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J. Infect. Dis. 1999; 180: 93-98.
31. Richardson, B., Stewart-John, G. C., Hughes, J. P. et al. Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers. J. Infect. Dis. 2003; 187: 736-740.
32. Nduati, R., Richardson, B. A., John, G. et al. Effect of breastfeeding on mortality among HIV-1 infected women: a randomised trial. Lancet 2001; 357: 1651-1655.
33. Coutsoudis, A., Coovadia, H., Pillay, K., Kuhn, L. AreHIV-infectedwomenwhobreastfeed at increased risk of mortality? AIDS 2001; 15: 653-655.
34. TheBreastfeeding and, International HIV Transmission Study (BHITS)Group. Mortality according to infant feeding modalityamongHIV-infected, breastfeedingwomenin sub-Saharan Africa. J. Acquir. Immune Defic. Syndr. 2005; 39: 430-438.
35. Gaillard, P., Fowler, M. G., Dabis, F. et al. Use of antiretroviral drugs to prevent HIV-1 transmission through breast-feeding: fromanimal studies to randomized clinical trials. J. Acquir. Immune Defic. Syndr. 2004; 35: 178-187.
36. Krebs, F. C., Miller, S. R., Malamud, D., Howett, M. K., & Wigdahl, B. Inactivation of humanimmunodeficiencyvirustype1bynonoxynol-9, C31G, ofanalkyl sulfate, sodium dodecyl sulfate. Antiviral Res. 1999; 43: 157-173.
37. Chantry, C. J., Morrison, P., Panchula, J. et al. Effects of lipolysis or heat treatment on HIV-1 provirus in breast milk. J. Acquir. Immune. Defic. Syndr. 2000; 24: 325-329.
38. Orloff, S. L., Wallingford, J. C., McDougal, J. S. Inactivation ofhumanimmunodeficiency virus type 1 in human milk: effects of intrinsic factors in human milk and of pasteurization. J. Hum. Lact. 1993; 9: 13-17.
39. Jeffery, B. S., Webber, L., Mokhondo, K. R., Erasmus, D. Determination of the effectiveness of inactivation of human immunodeficiency virus by Pretoria pasteurization. J. Trop. Pediatr. 2001; 47: 345-349.
40. The International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from fifteen prospective cohort studies. AIDS 2001; 15: 357-368.
41. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N. Engl. J. Med. 1999; 340: 977-987.
42. TheEuropeanModeofDeliveryCollaboration. Elective caesareansection versus vaginal delivery in preventing vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353: 1035-1037.
43. The Breastfeeding and HIV International Transmission Study Group. Late postnatal transmission of HIV-1 in breast-fed childern: an individual patient data meta-analysis. J. Infect. Dis. 2004; 189: 2154-2166.
44. Nduati, R., John, G., Mbori-Ngacha, D. et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. J. Am. Med. Assoc. 2000; 283: 1167-1174.
45. Piwoz, E. G., Kasonde, P., Vwalika, C. et al. The feasibility of early rapid breastfeeding cessation to reduce postnatal transmission ofHIVin Lusaka, Zambia. 14th International ConferenceonAIDS(Barcelona, Spain; July 7-12, 2002), ProgramandAbstracts, abstract TuPeF5393.
46. Semba, R. D., Miotti, P. G., Chiphangwi, J. D. et al. Maternal vitamin A deficiency and mother-to-child transmission of HIV-1. Lancet 1994; 343: 1593-1597.
47. Kumwenda, N., Miotti, P. G., Taha, T. E. et al. Antenatal vitamin A supplementation increases birthweight and decreases anemia, but does not prevent HIV transmission or decrease mortality in infants born to HIV-infected women in Malawi. Clin. Infect. Dis. 2002; 35: 618-624.
48. Coutsoudis, A., Pillay, K., Spooner, E. et al. Randomized trial testing the effect of vitamin Asupplementation on pregnancy outcomes and early mother-to-child HIV-1 transmission in Durban, South Africa. AIDS 1999; 13: 1517-1524.
49. Fawzi, W. W., Msamanga, G. I., Hunter, D. et al. Randomizedtrial of vitamin supplements in relation to transmission of HIV-1 through breastfeeding and early child mortality. AIDS 2002; 16: 1935-1944.
50. St. Louis, M., Kamenga, M., Brown, C. et al. Risk of perinatal HIV-1 transmission according to maternal immunologic, virologic, and placental factors. J. Am. Med. Assoc. 1993; 269: 2853-2859.
51. Temmerman, M., O'Nyong's, A., Bwayo J. et al. Risk factors for mother-to-child transmission of human immunodeficiency virus-1 infection. Am. J. Obstet. Gynecol. 1995; 172: 700-705.
52. Wabwire-Mangen, F., Gray, R. H., Mmiro, F. A. et al. Placental membrane inflammation and risks of maternal-to-child transmission of HIV-1 in Uganda. AIDS 1999; 22: 379-385.
53. Kafulafula, G., Martinson, F., Msamanga, G., Sinkala, M., and the HIVNET 024 Team Phase III Trial of Antibiotics to Reduce Chorioamnionitis-Associated MTCT of HIV. XV International AIDS Conference (Bangkok, Thailand; July 11-16, 2004) Program and Abstracts (abstract ThOrC1418).
54. Coutsoudis, A., Pillay, K., Kuhn, L., Spooner, E., Tsai, W. Y., Coovadia, H. M. Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa. AIDS 2001; 15: 379-387.
55. Hiff, P. J., Piwoz, E. G., Tavengwa, N. V. et al. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival. AIDS. 2005; 19(7): 699-708.
56. Haider, R., Ashworth, A., Kabir, I., Huttly, S. R. Effect of community-based peer counsellorsonexclusivebreastfeedingpractices inDhaka, Bangladesh: arandomisedcontrolled trial. Lancet 2000; 356: 1643-1647.
57. Van de Perre, P., Hitimana, D. G., Simonon, A. et al. Postnatal transmission of HIV-1 associated with breast abscess. Lancet 1992; 339: 1490-1491.
58. Ekpini, E. R., Wiktor, S. Z., Satten, G. A. et al. Late postnatal mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire. Lancet 1997; 349: 1054-1059.
59. Embree, J. E., Njenga, S., Datta, P. et al. Risk factors for postnatal mother-child transmission of HIV-1. AIDS 2000; 14: 2535-2541.
60. Tavengwa, N., Piwoz, E., Gavin, L., Zunguza, C., Iliff, P., Humphrey, J. Development, implementation, and evaluation of a program to counsel women about infant feeding in the context of HIV. 14th International Conference on AIDS (Barcelona, Spain; July 7-12, 2002), Program and Abstracts, abstractMoPeF3881.
61. UNAIDS. 2004 Report on the Global AIDS epidemic. (http://www. unaidṣorg).
62. Read, J. S. Preventing mother-to-child transmission of HIV: the USA experience. Prenat. Neonat. Med. 1999; 4: 391-397.
63. Centers for Disease Control and Prevention. U. S. Public Health Service recommendations forhumanimmunodeficiency virus counseling and voluntary testing for pregnant women. Morb. Mortal. Wkly Rep. 1995; 44 (RR-7): 1-15.
64. Lindegren, M. L., Byers, R. H. Jr, Thomas, P. et al. Trends in perinatal transmission of HIV/AIDS in the United States. J. Am. Med. Assoc. 1999; 282: 531-538.
65. Centers for Disease Control and Prevention. Entry into prenatal care-United States, 1989-1997. Morb. Mortal. Wkly Rep. 2000; 49 (18): 393-398.
66. Mills, W. A., Martin, D. L., Bertrand, J. R., Belongia, E. A. Physicians' practices and opinions regarding prenatal screening for human immunodeficiency virus and other sexually transmitted diseases. Sex. Transm. Dis. 1998; 25: 169-175.
67. Phillips KA, Morrison KR, Sonnad SS, BleeckerT. HIV counseling and testing of pregnant women and women of childbearing age by primary care providers: self-reported beliefs and practices. Acquir. Immune Defic. Hum. Retrovirol. 1997; 14: 174-178.
68. Institute ofMedicine (IOM). (1998) Reducing the Odds: Preventing Perinatal Transmission of HIV in the United States. Washington, DC: National Academy Press.
69. Centers for Disease Control and Prevention. Advancing HIV prevention: new strategies for a changing epidemic-United States, 2003. Morb. Mortal. WklyRep. 2003; 52(15): 329-332.
70. Cartoux, M., Msellati, P., Meda, N. et al. Attitude of pregnant women toward HIV testing in Abidjan, Cote d'Ivoire and Bobo-Dioulasso, Burkina Faso. AIDS 1998; 12: 2337-2344.
71. Centers for Disease Control. Current recommendations for assisting in the prevention of perinatal transmission of human T-lymphotropic virus type III/lymphadenopathyassociated virus and acquired immunodeficiency syndrome. Morb. Mortal. Wkly Rep. 1985; 34: 721-726.
72. American Academy of Pediatrics, Committee on Pediatric AIDS. Human milk, breastfeeding, and transmission ofhumanimmunodeficiency virus in theUnited States. Pediatrics. 1995; 96: 977-979.
73. Read, J. S., and the Committee on Pediatric AIDS, American Academy of Pediatrics. Human milk, breastfeeding, and transmission of human immunodeficiency virus in the United States. Pediatrics 2003; 112: 1196-1205.
74. Bertolli, J. M., Hsu, H., Frederick, T. et al. Breastfeeding among HIV-infected women, Los Angeles and Massachusetts, 1988-1993. 11th World AIDS Conference, Vancouver, 1996. AbstractWe. C. 3583.
75. Simonds, R. J., Steketee, R., Nesheim, S. et al. Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV. AIDS 1998; 12: 301-308.
76. Mbori-Ngacha, D., Nduati, R., John, G. et al. Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women: a randomized clinical trial. J. Am. Med. Assoc. 2001; 286: 2413-2420.
77. WorldHealth Organization. Report of theWHOTechnical Consultation on Behalf of the UNFPA/UNICEF/WHO/UNAIDS Inter-Agency Task Team on Mother-to-Child Transmission of HIV, October 11-13, 2000. New data on the prevention of mother-to-child transmission of HIV and their policy implications. Geneva, Switzerland: WHO; January 15, 2001. (Available at www. unaidṣorg/publications/documents/mtct/index. html).
78. American College of Obstetricians andGynecologists. Scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. ACOG Committee Opinion Number 234. Washington, D. C.: ACOG, May 2000.
79. Centers forDiseaseControl and Prevention. USPublicHealth ServiceTask Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in theUnited States. MMWR 1998; 47 (No. RR-2): 1-30. (Most recent revision of the guidelines available at http://AIDS Info. nih. gov.).
80. Dominguez, K. L., Lindegren, M. L., D'Almada, P. J. et al. Increasing trend of Cesarean deliveries in HIV-infected women in the United States from 1994 to 2000. J. Acquir. Immune Defic. Syndr. 2003; 33: 232-238.
81. Shaffer, N., Roongpisuthipong, A., Siriwasin, W. et al. Maternal viral load and perinatal HIV-1 subtype E transmission, Thailand. J. Infect. Dis. 1999; 179: 590-599.
82. The European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999; 13: 1377-1385.
83. Fiscus, S., Adimora, A, Schoenbach et al. Elective c-section may provide additional benefit in conjunction withmaternal combinationantiretroviral therapy to reduceperinatal HIVtransmission. XIIIWorldAIDSConference(July 2000, Durban, SouthAfrica), Abstract WePpC1388.
84. European Collaborative Study. Mother-to-child transmission of HIV infection: the era of highly active antiretroviral therapy. Clin. Infect. Dis. 2005; 40: 458-465.
85. Mrus, J. M., Goldie, S. J., Weinstein, M. C., Tsevat, J. The cost-effectiveness of elective Cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy. AIDS 2000; 14: 2543-2552.
86. Read, J. S., Cesarean section delivery to prevent vertical transmission ofhumanimmunodeficiency virus type 1: associated risks and other considerations. Ann. NY Acad. Sci. 2000; 918: 115-121.
87. Read, J. S., Preventing mother to child transmission of HIV: the role of caesarean section. Sex. Transm. Infect. 2000; 76: 231-232.
88. Ippolito, G., Puro, V., Heptonstall, J., Jagger, J., De Carli, G., Petrosillo, N. Occupational human immunodeficiency virus infection in health care workers: worldwide cases through September 1997. Clin. Infect. Dis. 1999; 28: 365-383.
89. Center for Disease Control and Prevention. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. Morb. Mortal Wkly Rep. 1994; 43 (RR11): 1-20.
90. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998; 47: 47 (No. RR-5) 43-82 (updates available at http://AIDSInfo. nih. gov).
91. Lyall, E. G. H., Blott, M., deRuiter, A. et al. Guidelines for themanagementofHIVinfection in pregnant women and the prevention of mother-to-child transmission. HIV Med. 2001; 2: 314-334.
92. Newell, M.-L., Rogers, M. Pregnancy and HIV infection: a EuropeanConsensus on management. AIDS 2002; 16 (Suppl. 2): S1-S18.
93. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach (2003 revision). (http://www. who. int/3by5/publications/documents/arvguidelines/en).
94. Mofenson, L. M., Munderi, P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. AIDS 2002; 30: 200-215.
95. Nolan, M., Fowler, M. G., Mofenson, L. M. Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. AIDS 2002; 30: 216-229.
96. Jourdain, G., Ngo-Giang-Huong, N., LeCoeur, S., et al. Intrapartumexposure to neivrapine and subsequent maternal responses to nevirapine-base antiretroviral therapy. N. Engl. J. Med. 2004; 351: 229-240.
97. Lockman, S., Smeaton, L. M., Shapiro, R. L. et al. Maternal and infant response to nevirapine (NVP)-based antiretroviral treatment (ART) following peripartum single-does NVP or placebo (Plc.) Program and Abstracts of the 43rd Annual Meeting of IDSA (San Francisco; October 6-9, 2005); abstract LB-5.
98. Hirsch, M. S., Brun-Vézinet, F., Clotet, B. et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA panel. Clin. Infect. Dis. 2003; 37: 113-128.
99. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001; 15: 309-320.
100. Johnson, V. A., Petropoulos, C. J., Woods, C. R. et al. Vertical transmission of multi-drug resistance human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J. Infect. Dis. 2001; 183: 1688-1693.
101. Guay, L. A., Musoke, P., Hom, D. L. et al. Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. AIDS 2002; 16: 1391-1400.
102. Biberfeld, G., Buonaguro, F., Lindberg, A., de The, G., Yi, Z., Zetterstrom, R. Prospects of vaccination as a means of preventing mother-to-child transmission of HIV-1. Acta Paediatr. 2002; 91: 241-242.